Abstract: The present invention pertains to a method for the generation of neurotoxin-sensitive, neuronal differentiated cells comprising the steps of: a) cultivating tumor cells which are able to differentiate into neuronal cells in a culture medium under conditions and for a time which primes said tumor cells for neuronal differentiation; and b) cultivating the tumor cells primed for neuronal differentiation of a) in a differentiation medium having an osmolality of 100 to 270 mOsm/kg, and comprising (i) B27 supplement and/or (ii) N2 supplement, for at least 3 days, thereby obtaining neurotoxin-sensitive, neuronal differentiated cells. The invention further relates to neurotoxin-sensitive, neuronal differentiated cells obtainable by the method of the invention.
Abstract: The present invention provides a method for producing a human cell aggregate containing a midbrain-hindbrain boundary neural progenitor tissue, including subjecting an aggregate of human pluripotent stem cells to suspension culturing in a serum-free medium containing insulin, and treating, in the suspension culturing, the aggregate of human pluripotent stem cells or a human cell aggregate derived therefrom with a ROCK inhibitor, a TGF? signal inhibitor, and a first fibroblast growth factor. Furthermore, the human cell aggregate containing the midbrain-hindbrain boundary neural progenitor tissue is subjected to suspension culturing in a serum-free medium to induce formation of a neuroepithelial structure by neural progenitor in the neural progenitor tissue, whereby the human cell aggregate containing the cerebellar plate tissue can be obtained.
Type:
Grant
Filed:
September 8, 2015
Date of Patent:
September 22, 2020
Assignees:
RIKEN, SUMITOMO CHEMICAL COMPANY, LIMITED
Abstract: The present disclosure provides methods for the treatment of a mammal having a neurological condition, disease, or injury. The methods involve increasing the number of functional GABAergic interneurons at or near the site of the neurological disease, injury, or condition.
Type:
Grant
Filed:
September 27, 2018
Date of Patent:
September 22, 2020
Assignee:
The Regents of the University of California
Inventors:
Arnold Kriegstein, John L. R. Rubenstein, Scott C. Baraban, Arturo Alvarez-Buylla
Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
Type:
Grant
Filed:
May 2, 2017
Date of Patent:
August 25, 2020
Assignee:
PROTHENA BIOSCIENCES LIMITED
Inventors:
Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour
Abstract: A combined treatment for nerve injury is provided. Accordingly there is provided a composition comprising a hyaluronic acid, a laminin polypeptide, an antioxidant and an anti-gliotic agent. Also provided are matrices and hydrogels of the composition and methods of using same.
Type:
Grant
Filed:
November 29, 2017
Date of Patent:
August 4, 2020
Assignees:
Ramot at Tel-Aviv University Ltd., The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center
Abstract: In alternative embodiments, provided are methods for increasing levels of and/or upregulating the expression of ApoA-I Binding Protein (APOA1BP, AIBP, or AI-BP) to treat, ameliorate, prevent, reverse, decrease the severity or duration of: a neuropathic pain, including an inflammation-induced neuropathic pain, a nerve or CNS inflammation, a, a post nerve injury pain, a post-surgical pain, a chemotherapeutic-induced peripheral neuropathy (CIPN) (e.g., cisplatin-induced allodynia) a neurodegeneration or neurodegenerative disease or condition, a migraine, and/or a hyperalgesia.
Type:
Grant
Filed:
December 5, 2016
Date of Patent:
August 4, 2020
Assignee:
The Regents of the University of California
Abstract: An anti-HMGB1 antibody comprising a light chain variable region comprising complementarity-determining regions or the like including amino acid sequences of SEQ ID NOs: 4 to 6, and a heavy chain variable region comprising complementarity-determining regions or the like including amino acid sequences of SEQ ID NOs: 10 to 12, or an anti-HMGB1 antibody comprising a light chain variable region or the like comprising an amino acid sequence of SEQ ID NO: 3, and a heavy chain variable region comprising an amino acid sequence or the like of SEQ ID NO: 9, and a composition for treating or preventing Alzheimer's disease, comprising the same as an active ingredient.
Type:
Grant
Filed:
August 8, 2017
Date of Patent:
August 4, 2020
Assignee:
National University Corporation Tokyo Medical and Dental University
Abstract: The present disclosure pertains to a mammalian cell culture genetically modified to express, and which expresses, a neublastin antibody polypeptide, or fragment thereof, in the culture, and to a neublastin antibody polypeptide, or fragment thereof, made by a mammalian cell culture genetically modified to express, and which expresses, the neublastin antibody polypeptide, or fragment thereof.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
July 21, 2020
Assignee:
Gloriana Therapeutics, Inc.
Inventors:
Alan Gilbert, Kyle McElearney, Terrence Michael Dobrowsky, Rashmi Rohit Kshirsagar
Abstract: The present invention relates to a method for producing mammalian neural plate border stem cells (NPBSCs), comprising: (a) differentiation of mammalian pluripotent stem cells by (a-i) culturing mammalian pluripotent stem cells in pluripotent stem cell medium for about 24 to about 96 hours, wherein the pluripotent stem cell medium comprises: (i) an inhibitor of the activin/TGF-? signalling pathway; (ii) an inhibitor of the BMP signalling pathway; (iii) an activator of the canonical WNT signalling pathway; and (iv) an activator of the Hedgehog signalling pathway; subsequently (a-ii) culturing the cells obtained in step (a-i) for about 24 to about 96 hours in a neural medium, wherein the neural medium comprises: (i) an inhibitor of the Activin/TGF-? signalling pathway; (ii) an inhibitor of the BMP signalling pathway; (iii) an activator of the canonical WNT signalling pathway; and (iv) an activator of the Hedgehog signalling pathway; subsequently (a-iii) culturing the cells obtained in step (a-ii) for about 24 to
Type:
Grant
Filed:
August 10, 2016
Date of Patent:
July 14, 2020
Assignee:
MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
Inventors:
Hans R. Schoeler, Jared L. Sterneckert, Michael Glatza, Peter Reinhardt
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
Type:
Grant
Filed:
July 10, 2019
Date of Patent:
July 14, 2020
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
Abstract: Provided herein are methods and compositions for treating disease-states associated with presence of increased number of ErbB4+ pro-inflammatory macrophages in a subject in need thereof. The methods include providing an activator of ErbB4 and administering a therapeutically effective amount of the activator to the subject. The compositions include an activator of ErbB4. In one embodiment, the activation of ErbB4 is Neuregulin-4.
Abstract: The present invention provides a composition for treating ischemic diseases or neuroinflammatory disorders, comprising a secretome of neural precursor cells (NPCs) as an active ingredient. The secretome of NPCs, of the present invention, reduces an ischemic injury site and enables neurological functions to recover by means of roles such as anti-inflammation, neovascularization regeneration, and activation and proliferation of inherent stem cells, thereby being usable as a therapeutic agent for ischemic diseases and degenerative nervous system disorders such as nerve damage diseases caused by inflammation. Particularly, the secretome of NPCs, of the present invention, has an excellent behavior improvement effect when administered multiple times.
Abstract: The described invention relates to a pharmaceutical composition comprising a therapeutically effect amount of a therapeutic agent, wherein the therapeutic agent is effective (1) to reduce tumor growth, migration, invasion or a combination and (2) improve subject survival relative to a control. The described invention also relates to a method of treating a subject with a tumor, the method comprising: (1) providing a pharmaceutical composition; and (2) administering the pharmaceutical composition, wherein the composition comprises a therapeutically effective amount of a therapeutic agent which is effective to reduce tumor growth, migration, invasion or a combination. The method may further comprise preparing therapeutic agent and preparing the pharmaceutical composition. The therapeutic agents include but are not limited to Wnt5a derivative peptides or Wnt5a antagonists or Wnt5a blocking antibody. The tumor comprises a population of cancer stem cells.
Abstract: Human pluripotent stem cells are differentiated in vitro into forebrain subdomain structures, which are then fused to generate an integrated system for use in analysis, screening programs, and the like.
Type:
Grant
Filed:
March 28, 2018
Date of Patent:
June 9, 2020
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Jimena Andersen, Fikri Birey, Sergiu P. Pasca
Abstract: Disclosed are compositions and methods of treating a neurodegenerative disease in an individual. The methods disclose administration of an Integrin ?4?1, Very Late Antigen-4 positive neural precursor cell (“VLA4+ NPC”) transfected with a lentivirus overexpressing wild type GCase to an individual having a neurodegenerative disorder. The neurodegenerative disease may include lipid storage diseases, for example Gaucher disease, Parkinson's disease (PD), Dementia with Lewy bodies.
Abstract: The present disclosure pertains to a mammalian cell culture genetically modified to express, and which expresses, a neublastin antibody polypeptide, or fragment thereof, in the culture, and to a neublastin antibody polypeptide, or fragment thereof, made by a mammalian cell culture genetically modified to express, and which expresses, the neublastin antibody polypeptide, or fragment thereof.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
June 2, 2020
Assignee:
Gloriana Therapeutics, Inc.
Inventors:
Alan Gilbert, Kyle McElearney, Terrence Michael Dobrowsky, Rashmi Rohit Kshirsagar
Abstract: Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease.
Type:
Grant
Filed:
October 25, 2017
Date of Patent:
May 26, 2020
Assignee:
MedImmune Limited
Inventors:
Maria Groves, Suzanne Gustavsson, Kina Höglund, Chris Lloyd, Adrian Nickson, Camilla Niva, Sylvia Simon, David Lowne, Fraser Welsh, Per-Ola Freskgärd
Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.
Type:
Grant
Filed:
January 11, 2017
Date of Patent:
May 5, 2020
Assignee:
Neuracle Sceince, Inc.
Inventors:
Jae Young Seong, Jong Ik Hwang, Woong Sun, Eun Bee Cho, Won-Ki Kim
Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
Type:
Grant
Filed:
July 2, 2016
Date of Patent:
April 28, 2020
Assignees:
PROTHENA BIOSCIENCES LIMITED, UNIVERSITY HEALTH NETWORK
Inventors:
Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
Abstract: The invention relates to humanized antibodies that bind to an epitope at the N-terminus of pyroglutamated amyloid beta (A? N3pE) peptide and to preventive and therapeutic treatment of diseases and conditions that are related to accumulation and deposition of amyloid peptides, such as amyloidosis, a group of disorders and abnormalities associated with pyroglutamated amyloid peptide, like Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy and other related aspects. More specifically, it pertains to the use of humanized monoclonal antibodies to bind pyroglutamated amyloid beta peptide in plasma, brain, and cerebrospinal fluid to prevent accumulation or to reverse deposition of A? N3pE within the brain and in various tissues in the periphery, and to alleviate amyloidosis. The present invention further pertains to diagnostic assays for the diagnosis of amyloidosis using the humanized antibodies of the invention.
Type:
Grant
Filed:
January 10, 2018
Date of Patent:
March 31, 2020
Assignee:
Probiodrug AG
Inventors:
Martin Kleinschmidt, Jens-Ulrich Rahfeld, Anke Piechotta, Stephan Schilling, Stephen Gillies